QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the ...
Credit: Getty Images Investigators explore the biomarker potential of circulating tumor DNA and tumor suppressor gene status. Elevated circulating tumor DNA fraction and tumor suppressor gene loss are ...
QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S.
Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal approaches.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results